Diagnostik og behandling af maturity onset diabetes of the young type 3

Kathrine Rose; Alexander Sidelmann Christensen; Heidi Storgaard; Sofie Hædersdal; Torben Hansen; Filip Krag Knop; Tina Vilsbøll

Diagnostik og behandling af maturity onset diabetes of the young type 3

Translated title of the contribution: Diagnosis and treatment of maturity onset diabetes of the young type 3

Kathrine Rose, Alexander Sidelmann Christensen, Heidi Storgaard, Sofie Hædersdal, Torben Hansen, Filip Krag Knop, Tina Vilsbøll

Department of Clinical Medicine

Abstract

Maturity onset diabetes of the young type 3 (MODY3) is the most prevalent type of monogenetic diabetes. Treatment guidelines differ from both Type 1 diabetes and Type 2 diabetes. First-line treatment is a long-acting sulphonylurea, which lowers the plasma glucose level effectively, however with the risk of hypoglycaemia. When hypoglycaemia is a problem, short-acting sulphonylureas, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors may be used as alternatives. Metformin, glitazones and sodium glucose transporter 2-inhibitors have only limited applicability in MODY3. Further research needs to evaluate combinational therapy.

Translated title of the contribution	Diagnosis and treatment of maturity onset diabetes of the young type 3
Original language	Danish
Article number	V06170502
Journal	Ugeskrift for Laeger
Volume	180
Number of pages	6
ISSN	0041-5782
Publication status	Published - 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

http://ugeskriftet.dk/videnskab/diagnostik-og-behandling-af-maturity-onset-diabetes-young-type-3

Cite this

@article{cee947e1775a426e84d4c06849bd7e46,

title = "Diagnostik og behandling af maturity onset diabetes of the young type 3",

abstract = "Maturity onset diabetes of the young type 3 (MODY3) is the most prevalent type of monogenetic diabetes. Treatment guidelines differ from both Type 1 diabetes and Type 2 diabetes. First-line treatment is a long-acting sulphonylurea, which lowers the plasma glucose level effectively, however with the risk of hypoglycaemia. When hypoglycaemia is a problem, short-acting sulphonylureas, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors may be used as alternatives. Metformin, glitazones and sodium glucose transporter 2-inhibitors have only limited applicability in MODY3. Further research needs to evaluate combinational therapy.",

keywords = "Diabetes Mellitus, Type 2/diagnosis, Humans, Hypoglycemic Agents/therapeutic use, Insulin-Secreting Cells/metabolism, Sulfonylurea Compounds/therapeutic use",

author = "Kathrine Rose and Christensen, {Alexander Sidelmann} and Heidi Storgaard and Sofie H{\ae}dersdal and Torben Hansen and Knop, {Filip Krag} and Tina Vilsb{\o}ll",

year = "2018",

language = "Dansk",

volume = "180",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

}

TY - JOUR

T1 - Diagnostik og behandling af maturity onset diabetes of the young type 3

AU - Rose, Kathrine

AU - Christensen, Alexander Sidelmann

AU - Storgaard, Heidi

AU - Hædersdal, Sofie

AU - Hansen, Torben

AU - Knop, Filip Krag

AU - Vilsbøll, Tina

PY - 2018

Y1 - 2018

N2 - Maturity onset diabetes of the young type 3 (MODY3) is the most prevalent type of monogenetic diabetes. Treatment guidelines differ from both Type 1 diabetes and Type 2 diabetes. First-line treatment is a long-acting sulphonylurea, which lowers the plasma glucose level effectively, however with the risk of hypoglycaemia. When hypoglycaemia is a problem, short-acting sulphonylureas, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors may be used as alternatives. Metformin, glitazones and sodium glucose transporter 2-inhibitors have only limited applicability in MODY3. Further research needs to evaluate combinational therapy.

AB - Maturity onset diabetes of the young type 3 (MODY3) is the most prevalent type of monogenetic diabetes. Treatment guidelines differ from both Type 1 diabetes and Type 2 diabetes. First-line treatment is a long-acting sulphonylurea, which lowers the plasma glucose level effectively, however with the risk of hypoglycaemia. When hypoglycaemia is a problem, short-acting sulphonylureas, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors may be used as alternatives. Metformin, glitazones and sodium glucose transporter 2-inhibitors have only limited applicability in MODY3. Further research needs to evaluate combinational therapy.

KW - Diabetes Mellitus, Type 2/diagnosis

KW - Humans

KW - Hypoglycemic Agents/therapeutic use

KW - Insulin-Secreting Cells/metabolism

KW - Sulfonylurea Compounds/therapeutic use

M3 - Tidsskriftartikel

C2 - 29429476

SN - 0041-5782

VL - 180

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

M1 - V06170502

ER -

Diagnostik og behandling af maturity onset diabetes of the young type 3

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this